Urban Stays Elevated
SHENZHEN, China, Aug. 10, 2026 /PRNewswire/ -- Four Seasons Hotel Shenzhen unveils a suite accommodation package, designed to enhance stays in the central business district of Futian. Located steps from the Shenzhen Convention and Exhibition Center and surrounded by key commercial and cultural landmarks, the Hotel offers unmatched convenience for American business travelers and tourists visiting one of China's most dynamic cities. Whether landing directly from overseas or arriving via bullet train, guests can reach the Hotel with exceptional speed and ease via a robust transport network.
Valid through 2026, the Experience More package enhances suite stays with a spending credit of CNY 888, inviting guests to make the most of their time at Four Seasons Hotel Shenzhen with exquisite dining, restorative wellness treatments, and other curated experiences. The additional credit can be utilized for a wide range of Hotel offerings, creating an unforgettable urban retreat for both work and leisure travelers.
Merging contemporary style with timeless hospitality, Four Seasons Hotel Shenzhen unfolds a remarkable vision of luxury against the backdrop of Shenzhen's vibrant energy. Home to 266 rooms, including 32 spacious suites, the property features multiple refined restaurants and lounges, indoor and outdoor pools, a serene full-service spa, and a 24-hour fitness center offering open views. Guests staying in suites also enjoy access to the 29th-floor Executive Club Lounge with gourmet dining, express check-in and bespoke concierge services.
Situated in the bustling Futian district, the Hotel provides exceptional access to Shenzhen's premier transportation hubs and landmark attractions. Shenzhen Bao'an International Airport is 35 minutes away by car, while a short 10-minute journey connects guests to the high-speed rail at Futian Station. Upscale shopping malls, green public spaces and famed cultural attractions are all within walking distance, making the Hotel an ideal base for exploring Shenzhen's diverse delights.
The Experience More suite package, alongside the Hotel's coveted location and extensive amenities, makes Four Seasons Hotel Shenzhen a premier choice for international guests visiting one of China's most exciting cities – whether for business or pleasure.
About Four Seasons Hotel Shenzhen
The Four Seasons Hotel Shenzhen is ideally located in the heart of the commercial district of Futian, across the Shenzhen Conference & Exhibition Center and a short walk from the Civic Center which houses the city's Municipal Hall and Museum as well as near the famed Shenzhen Concert Hall and Library. The Hotel is surrounded by 3 modern shopping malls and is a few steps away from the subway metro station and 10-minute drive to two Hong Kong borders of Huanggang and Futian. Built along contemporary lines, the Hotel features 266 rooms inclusive of 32 suites, a Club Lounge, Business Centre, four food and beverage outlets, and a grand ballroom with five other function venues plus unique outdoor multilevel terraces.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Four Seasons Hotel Shenzhen Introduces Exclusive Suite Offer in Futian's Heart
— Argentine biopharmaceutical company in July, South American public health institution in August sign consecutive KRNA material transfer agreements
— Two of five cumulative MTAs now in Latin America, as company accelerates entry into the region's pharmaceutical market
SEOUL, South Korea, Aug. 10, 2026 /PRNewswire/ -- Dx&Vx (DXVX, KRX: 180400), a biopharmaceutical company, announced that it signed two material transfer agreements (MTAs) in Latin America within a two-month span in July and August, both related to its room-temperature, long-term nucleic acid stabilization platform, KRNA. Following its first Latin American agreement with an Argentine biopharmaceutical company in July, the company signed a second agreement in August with one of the region's leading public health institutions, securing validation from both private and public-sector partners.
Private and Public Partners Secured Within Two Months
The Argentine partner is a top-tier local vaccine developer and manufacturer; the two companies finalized their agreement about a month after first meeting at BIO International Convention (BIO USA) in June. The South American public health institution, by contrast, signed only after roughly 10 months of technical review following an initial meeting last October. The institution manufactures vaccines directly for distribution across the region and previously took part in COVID-19 vaccine production for global pharmaceutical companies during the pandemic. Per the terms of both agreements, the names of the two institutions will not be disclosed.
Passing Both Fast-Track and Rigorous Validation
One agreement closed in a month with a private company; the other followed a 10-month, multi-department review by a public institution. That KRNA technology passed through both divergent paths suggests it has met the standards of speed-focused private companies as well as the rigorous safety and public-interest criteria of public institutions.
With these agreements, Dx&Vx's cumulative KRNA MTAs now total five, two of which were signed in Latin America within two months. The company noted that demand for room-temperature storage technology is especially high in regions where maintaining ultra-cold chain infrastructure is difficult — a description that broadly fits Latin America, given its tropical and subtropical climates and many less-accessible inland areas.
Latin America: The World's Fastest-Growing Pharmaceutical Market
The Latin American pharmaceutical market is projected to grow from USD 136 billion in 2025 to USD 250.6 billion by 2034, a CAGR of 7.03% (MarketDataForecast). The biopharmaceutical segment is expanding even faster, from USD 35.6 billion in 2025 to USD 81.6 billion by 2034, a CAGR of 9.67%. Argentina's market alone is expected to grow from USD 12.3 billion in 2025 to USD 21.8 billion by 2034 (IMARC Group).
"Objective Proof of Our Technology's Excellence" — CEO Kwon Kyu-Chan
Dx&Vx CEO Kwon Kyu-Chan said, "The Argentine agreement, finalized just a month after our first meeting, once again objectively demonstrated the excellence of our technology. The agreement with the public health institution carries particular significance, having followed nearly a year of engagement, and we will do our utmost to build on this foothold in Latin America's public procurement market to secure further partnerships and licensing-out achievements."
About KRNA
KRNA is a room-temperature, long-term nucleic acid stabilization platform developed by Dx&Vx, trademarked last year under a name reflecting "Kinetic RNA". The platform applies to a wide range of nucleic acid-based modalities, including mRNA vaccines, RNA-based therapeutics, DNA vaccines, aptamers, gene therapies, and gene-editing tools. Once material transfer is complete, partners conduct their own stability testing under internal protocols — a critical validation step toward a potential license-out agreement.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Dx&Vx Signs Two Material Transfer Agreements in Latin America Within Two Months -- "Technology Validated Across Both Public and Private Sectors"
